XGEVA sol inj 120 mg/ml ser pré 1 ml
7680695200010
CH-69520
M05BX04
07.16.1.
Reimbursement limitations:
XGEVA3
Remboursement pour les patients atteints de tumeurs solides présentant des métastases osseuses, en association avec …
1 / 3
google
Details
- Product number
- 6952001
- CPT
- -
- Packaging group
- 1
- Unit
- Fertigspritze(n)
- Composition
- denosumabum 120 mg, sorbitolum 37 mg, phenylalaninum 6.1 mg, acidum aceticum glaciale, polysorbatum 20, natrii hydroxidum q.s. ad pH, aqua ad iniectabile q.s. ad solutionem pro 1 ml corresp. natrium max. 0.6 mg.
Articles (1)
XGEVA 120 mg/1 ml, Injektionslösung in einer Fertigspritze
Injektionslösung
1
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
(N/A)
|
120.0 MG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
37.0 MG | Substance | HBESI |
|
(N/A)
|
6.1 MG | Substance | HBESI |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HBESI |
Reimbursement information
Public price
CHF 429.50
Specialties list
Yes
Generic
No
Reimbursement limitation
SL addition date:
01/01/2025
Authorization holder
Amgen Switzerland AG
6343 Risch
Authorization information
- Swissmedic authorization number
- 69520
- Drug name
- XGEVA, Injektionslösung in einer Fertigspritze
- Galenic form
- INLFS
- ATC Code
- M05BX04
- Authorization status
- Z
- Dispensation category
- A
- First authorization
- 18/09/2024
- Authorization expiration date
- 17/09/2029
- IT number
- 07.16.1.
- Domain
- Human medicine
Packaging details
- Description (FR)
- XGEVA sol inj 120 mg/ml ser pré 1 ml
- Description (DE)
- XGEVA Inj Lös 120 mg/ml Fertspr 1 ml
- Market launch
- 18/09/2024
- Narcotic (BTM)
- No